Two-Drug attack on Tough-to-Treat kidney cancer
NCT ID NCT06053658
Summary
This study is testing whether combining the drugs tivozanib and nivolumab can help control advanced non-clear cell kidney cancer. It will enroll about 48 adults with this specific type of cancer who have had up to one prior treatment. The main goals are to see if the combination is effective and to monitor its safety and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.